Trial Outcomes & Findings for Transcranial Laser Therapy, Continuous and Pulsed Light, for Major Depressive Disorder (ELATED-3) (NCT NCT02959307)

Last Updated: 2020-09-21

Results Overview

This is a brief (16-item) clinician-rated inventory of core depressive symptoms such as sleep, depressed mood, appetite, concentration, suicidal ideation, interest, energy, psychomotor retardation or agitation. Scores range from 0-27, higher scores indicating greater depression severity.

Recruitment status

COMPLETED

Study phase

Target enrollment

49 participants

Primary outcome timeframe

6 weeks - Sequential-parallel comparison design

Results posted on

2020-09-21

Participant Flow

Participant milestones

Participant milestones
Measure	Transcranial Light Therapy Transcranial light therapy penetrates the skin and brain using light energy and, the light energy may activate under-stimulated brain regions. Transcranial Light Therapy: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.	Sham Transcranial Light Therapy For the sham group, The transcranial light therapy device uses nonpenetrating light emitting diode light energy. The sham controls for which participants improve from the actual transcranial light therapy treatment and which participants improve during the study for reasons other than the therapy Transcranial Light Therapy: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions. Sham Transcranial Light Therapy: The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
Phase 1 STARTED	18	31
Phase 1 COMPLETED	15	23
Phase 1 NOT COMPLETED	3	8
Phase 2 STARTED	28	10
Phase 2 COMPLETED	26	10
Phase 2 NOT COMPLETED	2	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Transcranial Laser Therapy, Continuous and Pulsed Light, for Major Depressive Disorder (ELATED-3)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Transcranial Light Therapy n=18 Participants Transcranial light therapy penetrates the skin and brain using light energy and, the light energy may activate under-stimulated brain regions. Transcranial Light Therapy: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.	Sham Transcranial Light Therapy n=31 Participants For the sham group, The transcranial light therapy device uses nonpenetrating light emitting diode light energy. The sham controls for which participants improve from the actual transcranial light therapy treatment and which participants improve during the study for reasons other than the therapy Transcranial Light Therapy: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions. Sham Transcranial Light Therapy: The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.	Total n=49 Participants Total of all reporting groups
Age, Continuous	37.222 years STANDARD_DEVIATION 15.509 • n=5 Participants	42.806 years STANDARD_DEVIATION 15.823 • n=7 Participants	40.755 years STANDARD_DEVIATION 16.137 • n=5 Participants
Sex: Female, Male Female	14 Participants n=5 Participants	21 Participants n=7 Participants	35 Participants n=5 Participants
Sex: Female, Male Male	4 Participants n=5 Participants	10 Participants n=7 Participants	14 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants n=5 Participants	2 Participants n=7 Participants	3 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	15 Participants n=5 Participants	25 Participants n=7 Participants	40 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	2 Participants n=5 Participants	4 Participants n=7 Participants	6 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants
Race (NIH/OMB) Asian	2 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	2 Participants n=5 Participants	2 Participants n=7 Participants	4 Participants n=5 Participants
Race (NIH/OMB) White	13 Participants n=5 Participants	27 Participants n=7 Participants	40 Participants n=5 Participants
Race (NIH/OMB) More than one race	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Age of Depressive Onset	17.294 years STANDARD_DEVIATION 9.973 • n=5 Participants	23.429 years STANDARD_DEVIATION 16.089 • n=7 Participants	21.111 years STANDARD_DEVIATION 14.285 • n=5 Participants

PRIMARY outcome

Timeframe: 6 weeks - Sequential-parallel comparison design

Population: Sham Group in Phase 1 accounts for all subjects Receiving Sham. Patients in Sham within the first phase would be re-randomized to either NIR or Sham after completion of the initial 6 weeks. 2 participants in Sham did not have scores collected, as such the Sham group for Phase 1 consists of 29 participants rather than the total 31.

Outcome measures

Outcome measures
Measure	Transcranial Light Therapy n=18 Participants Transcranial light therapy penetrates the skin and brain using light energy and, the light energy may activate under-stimulated brain regions. Transcranial Light Therapy: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.	Sham Transcranial Light Therapy n=29 Participants For the sham group, The transcranial light therapy device uses nonpenetrating light emitting diode light energy. The sham controls for which participants improve from the actual transcranial light therapy treatment and which participants improve during the study for reasons other than the therapy Transcranial Light Therapy: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions. Sham Transcranial Light Therapy: The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
Quick Inventory of Depressive Symptomatology-Phase 1	11.06 score on a scale Standard Deviation 3.78	11.24 score on a scale Standard Deviation 4.83

PRIMARY outcome

Timeframe: 6 weeks - Sequential-parallel comparison design

Outcome measures

Outcome measures
Measure	Transcranial Light Therapy n=11 Participants Transcranial light therapy penetrates the skin and brain using light energy and, the light energy may activate under-stimulated brain regions. Transcranial Light Therapy: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.	Sham Transcranial Light Therapy n=7 Participants For the sham group, The transcranial light therapy device uses nonpenetrating light emitting diode light energy. The sham controls for which participants improve from the actual transcranial light therapy treatment and which participants improve during the study for reasons other than the therapy Transcranial Light Therapy: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions. Sham Transcranial Light Therapy: The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
Quick Inventory of Depressive Symptomatology(QIDS)-Phase 2	10.45 score on a scale Standard Deviation 5.751	9.14 score on a scale Standard Deviation 5.551

SECONDARY outcome

Timeframe: 6 weeks - Sequential-parallel comparison design

Population: Patients in Sham within the first phase would be re-randomized to either NIR or Sham after completion of the initial 6 weeks. There were two participants in the Sham group who did not have scores for the primary analysis (QIDS), we decided to include them in the secondary analysis (HAMD) as they had scores.

assessment of the patient's depressive symptoms, using a structured interview and defined anchor points. The Hamilton Depression Rating Scale aims to quantify the degree of depression in patients who already have a diagnosis of major depression. Score ranges from 0-52. Higher score indicates greater severity of depression.

Outcome measures

Outcome measures
Measure	Transcranial Light Therapy n=18 Participants Transcranial light therapy penetrates the skin and brain using light energy and, the light energy may activate under-stimulated brain regions. Transcranial Light Therapy: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.	Sham Transcranial Light Therapy n=31 Participants For the sham group, The transcranial light therapy device uses nonpenetrating light emitting diode light energy. The sham controls for which participants improve from the actual transcranial light therapy treatment and which participants improve during the study for reasons other than the therapy Transcranial Light Therapy: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions. Sham Transcranial Light Therapy: The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
Hamilton Depression Rating Scale - 17 Items(Phase 1)	16.28 score on a scale Standard Deviation 5.345	15.81 score on a scale Standard Deviation 6.685

SECONDARY outcome

Timeframe: 6 weeks - Sequential-parallel comparison design

Population: This group consists of all sham participants that did not respond to Sham in Phase 1 and were re-randomized into Phase 2. Therefore, of the 29 participants in Sham, 5 participants were responders, 4 were not re-randomized. 1 participant was not assessed with HAMD but was assessed with primary measure (QIDS), as such there are 10 in TLT group.

Outcome measures

Outcome measures
Measure	Transcranial Light Therapy n=10 Participants Transcranial light therapy penetrates the skin and brain using light energy and, the light energy may activate under-stimulated brain regions. Transcranial Light Therapy: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.	Sham Transcranial Light Therapy n=7 Participants For the sham group, The transcranial light therapy device uses nonpenetrating light emitting diode light energy. The sham controls for which participants improve from the actual transcranial light therapy treatment and which participants improve during the study for reasons other than the therapy Transcranial Light Therapy: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions. Sham Transcranial Light Therapy: The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
Hamilton Depression Rating Scale - 17 Items(Phase 2)	13.50 score on a scale Standard Deviation 6.151	14.14 score on a scale Standard Deviation 6.768

Adverse Events

Transcranial Light Therapy

Serious events: 0 serious events

Other events: 12 other events

Deaths: 0 deaths

Sham Transcranial Light Therapy

Serious events: 1 serious events

Other events: 17 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Transcranial Light Therapy n=31 participants at risk Transcranial light therapy penetrates the skin and brain using light energy and, the light energy may activate under-stimulated brain regions. Transcranial Light Therapy: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.	Sham Transcranial Light Therapy n=31 participants at risk For the sham group, The transcranial light therapy device uses nonpenetrating light emitting diode light energy. The sham controls for which participants improve from the actual transcranial light therapy treatment and which participants improve during the study for reasons other than the therapy Transcranial Light Therapy: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions. Sham Transcranial Light Therapy: The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
Psychiatric disorders Aborted Suicide Attempt	0.00% 0/31 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.	3.2% 1/31 • Number of events 1 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.

Other adverse events

Other adverse events
Measure	Transcranial Light Therapy n=31 participants at risk Transcranial light therapy penetrates the skin and brain using light energy and, the light energy may activate under-stimulated brain regions. Transcranial Light Therapy: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.	Sham Transcranial Light Therapy n=31 participants at risk For the sham group, The transcranial light therapy device uses nonpenetrating light emitting diode light energy. The sham controls for which participants improve from the actual transcranial light therapy treatment and which participants improve during the study for reasons other than the therapy Transcranial Light Therapy: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions. Sham Transcranial Light Therapy: The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
General disorders Headache	29.0% 9/31 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.	22.6% 7/31 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.
General disorders Worsening of Pre-Existing Condition	9.7% 3/31 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.	9.7% 3/31 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.
Respiratory, thoracic and mediastinal disorders Upper Respiratory Infection	6.5% 2/31 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.	19.4% 6/31 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.
Psychiatric disorders Insomnia	16.1% 5/31 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.	12.9% 4/31 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.
Psychiatric disorders Irritability With and Without Impulsivity	3.2% 1/31 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.	12.9% 4/31 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.
Psychiatric disorders Panic Attack	3.2% 1/31 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.	9.7% 3/31 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.
Psychiatric disorders Anxiety	0.00% 0/31 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.	6.5% 2/31 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.
General disorders Pressure on Forehead/Head	12.9% 4/31 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.	6.5% 2/31 • Timeframe of collection was during participation in the two phases of the study and follow up visit 1 week after completion. Therefore, the total timeframe of assessment is 13 weeks. Our participants flow differs for the following reasons: Per the SPCD design, subjects within the Sham group in Phase 1 are re-randomized in Phase 2 to receive either Sham or TLT treatment. Therefore, TLT group accounts for participants receiving TLT in the first phase as well as those re-randomized to TLT in their second phase. Participants in Sham account for all subjects randomized to sham in Phase 1, regardless of whether they were re-randomized to Sham or TLT in Phase 2.

Additional Information

Dr. Paolo Cassano

Massachusetts General Hospital

Phone: 617-643-9622

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place